CUREVAC NV (1CVAC.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1CVAC - NL0015436031 - Common Stock
4.386 EUR
-0.22 (-4.82%)
1CVAC gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. While 1CVAC has a great health rating, its profitability is only average at the moment. 1CVAC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
1CVAC had positive earnings in the past year.
In the past year 1CVAC had a positive cash flow from operations.
In the past 5 years 1CVAC reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: 1CVAC reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 28.11%, 1CVAC belongs to the best of the industry, outperforming 93.98% of the companies in the same industry.
With an excellent Return On Equity value of 33.02%, 1CVAC belongs to the best of the industry, outperforming 93.98% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 28.35%, 1CVAC belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
1CVAC has a Profit Margin of 37.93%. This is amongst the best in the industry. 1CVAC outperforms 89.16% of its industry peers.
With an excellent Operating Margin value of 40.58%, 1CVAC belongs to the best of the industry, outperforming 95.18% of the companies in the same industry.
The Gross Margin of 1CVAC (94.81%) is better than 91.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1CVAC is creating value.
Compared to 1 year ago, 1CVAC has about the same amount of shares outstanding.
1CVAC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1CVAC has an improved debt to assets ratio.
2.2 Solvency
1CVAC has an Altman-Z score of 9.26. This indicates that 1CVAC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 1CVAC (9.26) is better than 87.95% of its industry peers.
1CVAC has a debt to FCF ratio of 0.18. This is a very positive value and a sign of high solvency as it would only need 0.18 years to pay back of all of its debts.
1CVAC has a better Debt to FCF ratio (0.18) than 91.57% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that 1CVAC is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.05, 1CVAC is doing good in the industry, outperforming 67.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.26 |
ROIC/WACC3.96
WACC7.16%
2.3 Liquidity
A Current Ratio of 6.17 indicates that 1CVAC has no problem at all paying its short term obligations.
The Current ratio of 1CVAC (6.17) is better than 86.75% of its industry peers.
A Quick Ratio of 6.16 indicates that 1CVAC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.16, 1CVAC belongs to the top of the industry, outperforming 86.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 170.16% over the past year.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
Based on estimates for the next years, 1CVAC will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
1CVAC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.22% yearly.
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
1CVAC is valuated cheaply with a Price/Earnings ratio of 5.04.
Compared to the rest of the industry, the Price/Earnings ratio of 1CVAC indicates a rather cheap valuation: 1CVAC is cheaper than 96.39% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.43, 1CVAC is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for 1CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.04 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1CVAC is valued cheaper than 95.18% of the companies in the same industry.
1CVAC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1CVAC is cheaper than 95.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.03 | ||
| EV/EBITDA | 2.78 |
4.3 Compensation for Growth
The decent profitability rating of 1CVAC may justify a higher PE ratio.
A cheap valuation may be justified as 1CVAC's earnings are expected to decrease with -31.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
5. Dividend
5.1 Amount
1CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1CVAC (12/11/2025, 7:00:00 PM)
4.386
-0.22 (-4.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap987.60M
Revenue(TTM)510.51M
Net Income(TTM)193.64M
Analysts72.31
Price Target4.16 (-5.15%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)79.51%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)383.16%
Revenue beat(8)4
Avg Revenue beat(8)55.15%
Revenue beat(12)4
Avg Revenue beat(12)22.54%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.37%
PT rev (3m)-9.1%
EPS NQ rev (1m)-275%
EPS NQ rev (3m)-1786.66%
EPS NY rev (1m)0%
EPS NY rev (3m)11.05%
Revenue NQ rev (1m)220.62%
Revenue NQ rev (3m)140.45%
Revenue NY rev (1m)-14.05%
Revenue NY rev (3m)-14.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.04 | ||
| Fwd PE | N/A | ||
| P/S | 1.93 | ||
| P/FCF | 5.03 | ||
| P/OCF | 4.84 | ||
| P/B | 1.68 | ||
| P/tB | 1.76 | ||
| EV/EBITDA | 2.78 |
EPS(TTM)0.87
EY19.84%
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)0.87
FCFY19.86%
OCF(TTM)0.91
OCFY20.66%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.26 |
F-Score9
WACC7.16%
ROIC/WACC3.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5YN/A
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 1CVAC.MI FAQ
What is the ChartMill fundamental rating of CUREVAC NV (1CVAC.MI) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 1CVAC.MI.
What is the valuation status of CUREVAC NV (1CVAC.MI) stock?
ChartMill assigns a valuation rating of 5 / 10 to CUREVAC NV (1CVAC.MI). This can be considered as Fairly Valued.
What is the profitability of 1CVAC stock?
CUREVAC NV (1CVAC.MI) has a profitability rating of 6 / 10.
Can you provide the financial health for 1CVAC stock?
The financial health rating of CUREVAC NV (1CVAC.MI) is 9 / 10.